President Signs Opioids Bill Calling For Alternative Tech, More Pain-Control Research
Executive Summary
Industry groups praised newly enacted opioid-control legislation Oct. 24. The legislation will put more attention on existing medtech alternatives to addictive opioids and support research on new devices. Industry was positive about the new law, despite its expansion of sunshine reporting requirements that they oppose.
You may also be interested in...
FCA 2019: Key Issues Include DOJ Dismissal, Statute Of Limitations
Court rulings related to the False Claims Act (FCA) this year focused on whistleblower rules and further clarifying the theory of liability, given in the Supreme Court’s 2016 Escobar decision, Gibson Dunn health-care attorneys say.
No Pay Incentives Needed For Non-Opioid Pain Control Devices, CMS Says; Industry Disagrees
Medtech firms couldn’t convince the US Medicare agency to propose additional temporary payments under Medicare for non-opioid pain management device alternatives in its proposed rule for outpatient hospitals and ambulatory surgical centers. In response, industry advocacy group AdvaMed plans to gather more data in support of payment incentives before a mid-September deadline comes for comments on the rule.
What's Ahead In The US Senate: Support Builds For Bills To Lower Health-Care Costs, End Device Tax
The medtech industry should expect legislation to gain attention in the US Senate in the coming months to lower health-care costs and promote transparency to allow cost-conscious patients to shop for the most effective and lowest-priced surgical and advanced imaging procedures, as well as bills to repeal the device tax, key Senate health players say.